Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 天津力生制药股份有限公司是一家化学制药企业,公司主要从事化学药片剂、硬胶囊剂、滴丸剂、冻干粉针剂、水针剂、原料药等产品的生产销售.主要产品为高血压治疗药"寿比山"牌吲达帕胺片,广谱抗真菌治疗药"美扶"牌伊曲康唑胶囊,溃疡性结肠炎治疗药"畅美"牌奥沙拉嗪胶囊,哮喘病治疗药"盼得欣"牌富马酸福莫特罗片,解热镇痛药"三鱼"牌正痛片,老年痴呆症治疗药"阿海适"牌盐酸多奈派奇片,血栓疾病治疗药"益欣雪"胶囊,糖皮质激素类药"生化"牌注射用氢化可的松琥珀酸钠,滋补类制剂"三鱼"牌男宝胶囊,以及抑制胃酸回流剂"盖胃平"片等多个优质品种.公司为天津市科学技术委员会等部门共同认定的高新技术企业.公司于2003年获得全国五一劳动奖状,2006年、2007年获得天津市五一劳动奖状;2004年、2005年,公司获得"天津市优秀企业"称号.公司主要产品高血压治疗药"寿比山"牌吲达帕胺片被天津市人民政府授予"天津市名牌产品"称号.2008年5月19日,"寿比山"商标被天津市工商行政管理局认定为天津市著名商标,2009年5月24日该商标被国家工商行政管理总局商标局认定为驰名商标。
Main Business 医药产品研发、生产和销售
Legal Representative 张平
Top Executives
董事长：张平
董事：王福军,滕飞,王茜,张平,于克祥,刘浩
独立董事：雷英,张梅,方建新
Top 5 Shareholder
Shareholder name Nature Holding Date
天津金浩医药有限公司流通A股50.86%20/12/2024
天津市西青经济开发集团有限公司流通A股0.71%20/12/2024
蒋彩娟流通A股0.60%20/12/2024
孙治明流通A股0.50%20/12/2024
陈永泽流通A股0.49%20/12/2024
Company Secretary 马霏霏
Solicitors 嘉德恒时律师事务所
Auditors 中瑞岳华会计师事务所有限公司
Tel No 022-27641760
Fax No 022-27364239
Website www.lishengpharma.com
Email lisheng@lishengpharma.com
Company Address
Register: 天津市西青经济技术开发区赛达北一道16号
Office: 天津市西青经济技术开发区赛达北一道16号
Listing Date 23/04/2010
Shares Capital
Shares Capital: 257,895,388
Total A Share: 257,895,388
Listed A Share: 255,436,988
Non-tradable A Share: 2,458,400
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 1.970
DPS(RMB)* ¥ 0.600
NBV Per Share(RMB)* ¥ 26.610
Market Capitalization(RMB) 4.613B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.